Harmony Biosciences Holdings, Inc.·4

Jan 26, 4:44 PM ET

Zaeske Adam H. 4

4 · Harmony Biosciences Holdings, Inc. · Filed Jan 26, 2026

Research Summary

AI-generated summary of this filing

Updated

Harmony Biosciences CCO Adam Zaeske Receives 73,100-Share Awards

What Happened Adam H. Zaeske, Chief Commercial Officer of Harmony Biosciences (HRMY), received compensatory equity awards on January 22, 2026: a stock option award covering 56,900 underlying shares and restricted stock units (RSUs) covering 16,200 shares, for a total of 73,100 share-equivalents. Both awards were reported as grants (derivative transactions) at $0.00 per share (i.e., compensatory awards rather than open-market purchases).

Key Details

  • Transaction date: January 22, 2026; filing date: January 26, 2026 (timely filed within required Form 4 window).
  • Award types and amounts: 56,900-share option award; 16,200 RSUs; total 73,100 share-equivalents.
  • Reported price: $0.00 (compensatory grants).
  • Shares owned after the transaction: not specified in the provided excerpt of the filing.
  • Footnote F1 (options): 25% of the option shares vest on January 22, 2027, with the remainder vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to continued service.
  • Footnote F2 (RSUs): RSUs vest in four equal annual installments beginning January 22, 2027; each RSU converts to one share and has no expiration date.

Context These were company compensation awards (not open-market purchases or sales). The option and RSU grants are typical long-term incentive awards for executives and vest over multiple years contingent on continued service; they do not represent an immediate cash transaction or a sale of stock.

Insider Transaction Report

Form 4
Period: 2026-01-22
Zaeske Adam H.
CHIEF COMMERCIAL OFFICER
Transactions
  • Award

    Stock Option

    [F1]
    2026-01-22+56,90056,900 total
    Exercise: $36.76Exp: 2036-01-22Common Stock (56,900 underlying)
  • Award

    Restricted Stock Units

    [F2]
    2026-01-22+16,20016,200 total
    Common Stock (16,200 underlying)
Footnotes (2)
  • [F1]The stock option vests with respect to 25% of the underlying shares on January 22, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
  • [F2]The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
Signature
/s/ Christian Ulrich, Attorney-in-Fact|2026-01-26

Documents

1 file
  • 4
    form4-01262026_090126.xmlPrimary